A study to assess the effect of AZD0780 on the pharmacokinetics of rosuvastatin.

Exclusion Criteria

• -History or presence of gastrointestinal, hepatic or renal disease, or any other clinically significant disease or disorder
• -Any positive result on screening for serum hepatitis B surface antigen, hepatitis C antibody, or HIV.
• - Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) first vaccination within 30 days prior to randomization and second vaccination within 10 days of screening
• -Confirmed Coronavirus disease 2019 (COVID-19) infection at admission, by Polymerase chain reaction (PCR) test
• -Plasma donation within 1 month of screening or any blood donation/loss more than 500 mL during the 3 months prior to screening
• -History or presence of severe allergy/hypersensitivity
• -Current smokers or those who have smoked or used nicotine products (including e-cigarettes) within the 3 months prior to screening
• -Positive screen for drugs of abuse, alcohol, or cotinine at screening
• -Use of drugs with enzyme-inducing properties such as St John’s Wort within 3 weeks prior to the first administration of the study drug
• -Any clinically significant abnormalities in clinical chemistry, hematology, coagulation, urinalysis results, ECG or vital signs